• UK grants early access for Gilead's remdesivir in Covid-19

    1 month ago - By MedCity News

    The arrangement is analogous to the emergency use authorization that the drug received from the FDA earlier this month. Peer-reviewed data from the Phase III NIAID study of the drug were published Friday.
    Read more ...

     

  • Gilead study shows shorter five-day course of remdesivir works as well as 10-day one

    Gilead study shows shorter five-day course of remdesivir works as well as 10-day one

    1 month ago - By Reuters

    Gilead Sciences Inc, which has suggested that a shorter treatment duration could extend limited supplies of its drug remdesivir, on Wednesday published results of a study showing no significant difference in outcomes between 5- and 10-day courses of the drug for patients with severe COVID-19.
    Read more ...